Magnolia Medical Technologies

Magnolia Medical Technologies

Medical Equipment Manufacturing

Seattle, Washington 3,372 followers

Partnering with you to achieve near-zero blood culture contamination rates with Steripath

About us

Magnolia Medical Technologies is on a Mission to ZERO®. Today, we offer healthcare institutions a solution to some of their biggest hidden problems – contamination leading to misdiagnosis of bloodstream infections, including sepsis, which can lead to unnecessary and prolonged antibiotic therapy, and false-positive CLABSIs. Tomorrow, we aspire to create a world free of in-vitro diagnostic errors where rapid, accurate test results improve the lives of patients and providers alike. We know that setting new standards of care is a journey enabled by purposeful innovation, partnerships, and perseverance. As the first step of our journey, we have successfully developed and proven our evidence-based technology platform, Steripath, which we’ve coupled with unparalleled support to change clinical practices and prevent unnecessary patient harm as well as system-wide costs associated with the misdiagnosis of sepsis. Our mission is further enabled by reducing false-positive CLABSIs and leveraging our extensive intellectual property portfolio – consisting of over 100 issued method, apparatus, and design patents and 70 patent applications pending – to address other important sources of diagnostic error that are harmful to patients and costly to hospitals.

Industry
Medical Equipment Manufacturing
Company size
51-200 employees
Headquarters
Seattle, Washington
Type
Privately Held
Founded
2006
Specialties
Healthcare, Hospital, Emergency Departments, Antimicrobial Stewardship, Nursing, Medical Reimbursement, Sepsis Prevention, Accurate Blood Testing, Medical Devices, Hospital Reimbursement, Hospital, Medical Technology, Healthcare Technology, Blood Culture Collection, and Infectious Disease Prevention

Locations

  • Primary

    220 W Mercer St

    Suite 100

    Seattle, Washington 98119, US

    Get directions

Employees at Magnolia Medical Technologies

Updates

  • We're exhibiting at Premier Annual Breakthroughs Conference 2024!    Join us in booth 1429 from Wednesday, July 24 - Thursday, June 25 to learn about our mission to help all healthcare institutions eliminate sepsis misdiagnosis due to the preventable error of false-positive blood culture results caused by contamination. See you soon!

    • No alternative text description for this image
  • What does a 2.3% contamination rate mean hospital-wide? A typical hospital draws about 1,833 blood cultures a month. If they are at a 2.3% contamination rate, that translates to 42 people, 42 human beings, impacted by a false-positive blood culture every month. This translates to 506 patients a year. According to two peer-reviewed published studies in 2019, the average cost to the hospital per blood culture contamination event is around $4,700 (graphic uses a conservative $4,162 per event). This translates to over $2.1M in avoidable costs per year hospital-wide. #PatientSafety #HealthcareCosts

    • No alternative text description for this image
  • The old national 'standard' for blood culture contamination in the U.S. was <3%. But was this 'standard' good for patients? A typical hospital in the emergency department draws about 800 cultures a month. A 3% contamination rate translates to 25 people, 25 human beings, that are impacted by a false-positive blood culture every month. According to two peer-reviewed published studies in 2019, the average cost to the hospital per blood culture contamination event is around $4,700 (graphic below uses a conservative $4,162 per event). This translates to over $1.2M in avoidable costs per year in the ED alone. This is the clinical and economic impact to the typical hospital when blood culture contamination is at 3%. #PatientSafety #HealthcareCosts

    • No alternative text description for this image
  • We are excited to announce the launch of Magnolia Analytics, our highly innovative, technology-enabled service solution. This platform, which was developed in close collaboration with several large U.S. hospital systems, enables the robust quantification of clinical and economic value created by significantly reducing blood culture contamination to improve sepsis testing accuracy. With the launch of Magnolia Analytics, Magnolia Medical Technologies exclusively provides hospitals and healthcare systems with an end-to-end, software-driven solution to support sustained achievement of near-zero blood culture contamination rates. Read the full press release here: https://lnkd.in/gYJ2f-fA

    • No alternative text description for this image
  • 🏳️🌈 Happy Pride from Magnolia Medical Technologies! 🏳️🌈   In June (and every other month of the year), we stand with the LGBTQ community in celebrating love, diversity, and inclusion for all. At Magnolia Medical Technologies, we believe that everyone deserves to be their authentic selves and to be treated with respect and dignity in the workplace and out.   We are committed to creating an inclusive environment for our employees, customers, patients, and community. Join us in celebrating Pride and promoting equality and acceptance for all.

  • Stop by our booth 921 at ASM Microbe from June 14-16! Photographed in our booth (left) is Dr. Paul Goldenbaum, PhD. Dr. Goldenbaum is a Fellow of the American Academy of Microbiology, President of Texas Microbiology Consultants, LLC, and a member of the Magnolia Medical Technologies Medical and Scientific Advisory Board. Learn more about Dr. Goldenbaum and his contributions into blood culture technology by visiting https://lnkd.in/gHDUkFm3

    • No alternative text description for this image
  • We're exhibiting at ASM Microbe 2024 in Atlanta, June 14-16! Stop by booth 921 to learn how reducing blood culture contamination, which contributes to a misdiagnosis of sepsis and unnecessary administration of antibiotics like Vancomycin, proves to be one of the most effective methods in preventing multi-drug resistant organisms (MDROs) and avoiding antibiotic-related infections like Clostridioides difficile Infection (CDI). #ASMMicrobe2024 #Microbiology #ScienceConnection

    • No alternative text description for this image
  • We're exhibiting at #APIC24 this year in San Antonio, Texas! Join us in booth 1301 from Monday, June 3 - Wednesday, June 5 to learn more about evidence-based solutions to reduce your blood culture contamination rates. We will also be joining BD in booth 1227 to showcase our Steripath®Micro device, offered exclusively with BD Vacutainer® UltraTouch™ Push-Button Blood Collection Set to provide additional benefits.

    • No alternative text description for this image

Similar pages

Browse jobs

Funding